S0003704

EFV600mg+3TC300mg+TDF300mg tabs/PAC-30


Efavirenz 600mg + Lamivudine 300mg + Tenofovir disoproxil fumarate 300mg (equivalent to 245mg Tenofovir disoproxil), film coated tablets, bottle pack of 30
Indicative Price : Upon Request
Disclaimer: The images shown are for illustration purposes only and may not be an exact representation of the product. “No Generic Photo Available" means that there is not an image available for this product.

NOTE: The description below is for a standard product. It is not specific to patent status and pricing policies that may apply at country level. This information is available on request from Supply Division: Contact: supply@unicef.org


General Description:
Efavirenz 600mg + Lamivudine 300mg + Tenofovir Disoproxil Fumarate 300mg, equivalent to 245mg Tenofovir Disoproxil 300mg, film coated tablets, bottle pack of 30

Technical Specifications:
Each film coated tablet contains Efavirenz 600mg, Lamivudine 300mg and Tenofovir Disoproxil Fumarate 300mg, equivalent to 245mg Tenofovir Disoproxil as fixed dose combination.

Therapeutic class:
Efavirenz is a Non Nucleoside Reverse Transcriptase Inhibitor (NNRTI)
Lamivudine is Nucleoside Reverse Transcriptase Inhibitors (NRTI)
Tenofovir is a Nucleotide Reverse Transcriptase Inhibitor (NtRTI)

Standard shelf life:
2 years (24 months)

Other available formulations:
The product may also be available in other formulations, pack sizes, or in combinations with other ARVs.

Guidelines for use:
For more details, please click the links listed below:

WHO treatment guidelines


and

WHO Essential Medicines Library


or your regional national guidelines

For details about paediatric dosage schemes, please click the links listed below:

WHO HIV/AIDS


WHO Generic tool for assessing paediatric ARV dosing


Indications:
Management of HIV-1 infection in adults and adolescents over 12 years of age, and weighing more than 40kg. By mouth (oral), PO

Storage:
Do not store above 30ºC (86ºF)
Store in tightly closed original container
Keep out of reach and sight of children

Dispensing instructions:
Dispense in original container. Do not repack
Advise patient to take the medicine on empty stomach and at bedtime, especially in the first 2-4 weeks to reduce CNS effects.

Regulatory Status:
For latest updates, please click the links listed below:

List of WHO Prequalified Medicines


List of USFDA approved and tentatively approved items


Related Products